404 related articles for article (PubMed ID: 8683141)
1. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
2. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine.
Araga S; Blalock JE
Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437
[TBL] [Abstract][Full Text] [Related]
3. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
4. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis.
Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M
J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019
[TBL] [Abstract][Full Text] [Related]
5. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.
Agius MA; Richman DP
J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757
[TBL] [Abstract][Full Text] [Related]
6. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
Loutrari H; Kokla A; Tzartos SJ
Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
[TBL] [Abstract][Full Text] [Related]
7. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.
Xu L; Villain M; Galin FS; Araga S; Blalock JE
Cell Immunol; 2001 Mar; 208(2):107-14. PubMed ID: 11333143
[TBL] [Abstract][Full Text] [Related]
8. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
9. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
Meinl E; Klinkert WE; Wekerle H
Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
[TBL] [Abstract][Full Text] [Related]
10. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
Fujii Y; Lindstrom J
J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
[TBL] [Abstract][Full Text] [Related]
11. Paratope- and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies.
Verschuuren JJ; Graus YM; Tzartos SJ; van Breda Vriesman PJ; De Baets MH
J Immunol; 1991 Feb; 146(3):941-8. PubMed ID: 1988504
[TBL] [Abstract][Full Text] [Related]
12. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
Krolick KA; Yeh TM; Edlund SA
Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
[TBL] [Abstract][Full Text] [Related]
13. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
Gomez CM; Richman DP
J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
[TBL] [Abstract][Full Text] [Related]
15. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.
Morell SW; Trinh VB; Gudipati E; Friend A; Page NA; Agius MA; Richman DP; Fairclough RH
Mol Immunol; 2014 Mar; 58(1):116-31. PubMed ID: 24333757
[TBL] [Abstract][Full Text] [Related]
17. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Tzartos SJ; Sophianos D; Efthimiadis A
J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
[TBL] [Abstract][Full Text] [Related]
18. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.
Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A
Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538
[TBL] [Abstract][Full Text] [Related]
20. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains.
Wu B; Shenoy M; Goluszko E; Kaul R; Christadoss P
J Immunol; 1995 Apr; 154(7):3603-10. PubMed ID: 7897239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
